Question-and-Answer Session
Operator
(Operator Instructions) Our first question comes from Phil Nalbone from RBC Capital Markets.
Phil Nalbone - RBC Capital Markets
Hello, and congratulations on another pretty remarkable quarter. I wanted to address the shareholder rights plan, Rick. I think a lot of people will have questions about this. Is this renewal of the plan in response to anything specific or any perceived threats or is this just a routine exercise in corporate governance given that the existing plan was about 10 years old
Richard Packer
Yeah, the existing plan ends in June, so we weren't going to have another board meeting before it ended, so this was just a routine renewal of what we think is just a good corporate governance item for a company like ZOLL.
Phil Nalbone - RBC Capital Markets
Okay. But just to clear the decks here on I think a pretty salient issue. Do you perceive ZOLL to be in play, have there been overtures? Do you think the stock has been so egregiously undervalued that you would be likely to get a hostile bid?
Richard Packer
There's a whole bunch of questions tied into that question, Phil. Again, this is just the timing thing, this thing was going to expire. We needed to renew it because we think that's the good general thing. It is not in response to any outside events, it is what it is. As to the value of the company, we're almost getting back to where we were before our largest competitor was shutdown, so I think we made a lot of progress here. But don't tie anything together other than this thing was going to expire in June, and we feel that it's a good thing for ZOLL to have generally.
Phil Nalbone - RBC Capital Markets
Okay, great. Thanks for indulging me on those questions. I wanted to look again at the overseas performance, by our numbers ZOLL has averaged 33% revenue growth over the past eight quarters in the overseas markets and that's despite competing head-to-head with Physio in those markets for the entire duration. What do you think that tells us about ZOLL's ability to compete in a fair fight with Physio and to take market share and exactly why are you taking market share?
Richard Packer
I think it's pretty telling as to what's going on, and the international market doesn't even have some of the advantages that the domestic market has, for example, data. We're not as strong with our ZOLL data brand in international as we are domestically, so we can't even get the kind of leverage that I highlighted with Rural Metro internationally. And in spite of that, just head on head with defib on defib, we've had very, very strong growth. I think that is driven primarily by the strength of the product line and the unique aspects that our product line has, not just in its individual defib features but also this whole concept of there's more to resuscitation than just the shock, the AutoPulse, Real CPR Help are very, very important elements of driving the whole product line forward.
- To read the full transcript on Seeking Alpha, click here »
